GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Theratechnologies Inc.
Theratechnologies is a Canadian biopharmaceutical company focused on HIV treatment. Its stock price is dependent on sales of its drugs and progress in developing new therapies.
Share prices of companies in the market segment - Pharma immune
Theratechnologies Inc. is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly HIV. We classify it in the Pharmaceuticals (Immunology) segment because its drugs target the immune system. The chart below shows the performance of this specialized sector.
Broad Market Index - GURU.Markets
Theratechnologies is a Canadian biopharmaceutical company specializing in the development of drugs for the treatment of metabolic disorders and HIV. It is part of the GURU.Markets index and represents the biotech sector. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
THTX - Daily change in the company's share price Theratechnologies Inc.
Shares of Theratechnologies, a biopharmaceutical company, exhibit high volatility, as measured by change_co. This reflects sensitivity to the company's drug sales and development news. This metric is important for analyzing the pharmaceutical sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Theratechnologies Inc. is a biotech company. This chart highlights the sector's high volatility. Comparison with THTX, which focuses on HIV and cancer treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Theratechnologies is a biotech company specializing in the treatment of HIV and other metabolic disorders. Its shares are driven by news of sales of existing drugs and the results of trials of new ones. This dynamic is part of the overall volatility in the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Theratechnologies Inc.
Theratechnologies Inc.'s year-over-year performance tells the story of its HIV and cancer drug portfolio. Its market capitalization over 12 months reflects the sales volumes of its approved products, as well as progress in developing new drugs, which is key to its strategy of becoming a diversified biopharmaceutical company.
Annual dynamics of market capitalization of the market segment - Pharma immune
Theratechnologies Inc. is a commercial biopharmaceutical company focused on treating patients with HIV. The chart shows how its commercialization success, competition, and clinical trial results for new drugs influence its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Theratechnologies is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Theratechnologies Inc.
Theratechnologies is a biopharmaceutical company with commercialized products. Therefore, its monthly performance depends not only on news about new developments but also on quarterly sales reports for existing drugs. The chart shows the balance between stable revenue and expectations from oncology research.
Monthly dynamics of market capitalization of the market segment - Pharma immune
This chart reflects the dynamics of the biotech sector. For Theratechnologies, a company with commercial products, it's the backdrop. Its movements reflect how investors evaluate the balance between current sales and the potential of its oncology developments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Theratechnologies is a biopharmaceutical company specializing in drugs for the treatment of metabolic disorders, particularly in HIV patients. The full market chart allows you to assess how Theratechnologies' shares, as a commercial company in a niche market, perform relative to riskier biotechs and the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Theratechnologies Inc.
Theratechnologies Inc. is a Canadian biopharmaceutical company specializing in the treatment of HIV and other diseases. Its weekly stock price is driven by sales reports for its approved drugs and news about clinical trials.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Theratechnologies develops drugs for the treatment of HIV and oncology. These are highly competitive markets where success depends on the efficacy and safety of new drugs. Compare the company's performance with the pharmaceutical sector to understand how the market views its drugs against industry giants.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Theratechnologies is a pharmaceutical company whose stock moves on news about clinical trials. It's a classic example of an asset that doesn't correlate with the market. The chart clearly demonstrates how much its performance is driven by scientific news.
Market capitalization of the company, segment and market as a whole
THTX - Market capitalization of the company Theratechnologies Inc.
The market capitalization of Theratechnologies, a Canadian biotech company, reflects its focus on commercializing drugs for the treatment of HIV patients. This chart shows how investors value its existing products, as well as its efforts to expand into oncology.
THTX - Share of the company's market capitalization Theratechnologies Inc. within the market segment - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly those related to HIV. It has a significant share of this niche market. The chart shows the company's market share, which addresses specific medical problems.
Market capitalization of the market segment - Pharma immune
The chart below shows the overall value of the biotech sector. Theratechnologies is a Canadian company focused on treating patients with HIV and other metabolic disorders. Its market history exemplifies how to successfully commercialize drugs for niche but important patient groups while ensuring a stable business.
Market capitalization of all companies included in a broad market index - GURU.Markets
Theratechnologies is a Canadian pharmaceutical company specializing in developing drugs to treat rare diseases, such as lipodystrophy in HIV-infected patients. Its market capitalization reflects its niche expertise. The chart below shows the weighting of companies in this field.
Book value capitalization of the company, segment and market as a whole
THTX - Book value capitalization of the company Theratechnologies Inc.
Theratechnologies' foundation is its commercial HIV treatments and intellectual property in oncology research. The chart tells the story of a biotech company that uses revenue from its approved products to fund risky but potentially more valuable cancer research.
THTX - Share of the company's book capitalization Theratechnologies Inc. within the market segment - Pharma immune
Theratechnologies focuses on treating patients with specific diseases, such as HIV. The chart shows its share of commercial and R&D assets. This is its sales and marketing infrastructure that ensures access to its drugs.
Market segment balance sheet capitalization - Pharma immune
Theratechnologies, a pharmaceutical company, focuses on commercialization, making it less capital-intensive than giants with dozens of manufacturing plants. The graph below illustrates the scale of the pharmaceutical sector, highlighting its business model.
Book value of all companies included in the broad market index - GURU.Markets
Theratechnologies is a biopharmaceutical company focused on the treatment of HIV and other metabolic disorders. Its assets include its commercial drugs and R&D. Its stake in BCap_All provides the financial base that allows it to address the specific needs of patients.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Theratechnologies Inc.
Theratechnologies is a biopharmaceutical company. Its valuation is below book value, reflecting challenges in growing sales of its commercial products and investor concerns about the success of its developments.
Market to book capitalization ratio in a market segment - Pharma immune
Theratechnologies is a pharmaceutical company specializing in the treatment of HIV and other diseases. This metric reflects the extent to which its market valuation, based on its commercial products and developments, exceeds the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Theratechnologies is a Canadian biopharmaceutical company specializing in the treatment of HIV and other metabolic disorders. Its valuation depends on the success of its existing and future drugs. This chart shows how the market values niche pharmaceutical companies with commercialized products.
Debts of the company, segment and market as a whole
THTX - Company debts Theratechnologies Inc.
Theratechnologies, a biopharmaceutical company specializing in the treatment of metabolic disorders, including those associated with HIV, is using capital to commercialize its products. Its debt strategy is aimed at funding marketing and sales, as well as conducting clinical trials to expand the indications for its drugs.
Market segment debts - Pharma immune
Theratechnologies is a biopharmaceutical company focused on developing and commercializing drugs for rare diseases, such as HIV. Selling niche drugs requires a specific marketing strategy. This chart shows how the company funds its commercial operations and clinical research to expand the use of its drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Theratechnologies Inc.
Theratechnologies is a biopharmaceutical company specializing in HIV and oncology treatments. Commercialization and development of new drugs require significant financial resources. This chart shows the company's debt-to-equity ratio, providing insight into the company's financial strategy and its reliance on creditors to fund its operations.
Market segment debt to market segment book capitalization - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in drugs for the treatment of HIV and other diseases. The chart shows debt trends in their sector. It helps assess how the company manages the commercialization of its existing products and funds the development of new ones, and how its debt strategy compares to other players in the field.
Debt to book value of all companies in the market
Theratechnologies is a biopharmaceutical company specializing in HIV and oncology treatments. With approved products on the market, the company generates revenue. This total debt load chart helps assess its financial maturity. Does it use debt to fund commercial activities and research, or does it pursue a more conservative strategy, relying on its own funds?
P/E of the company, segment and market as a whole
P/E - Theratechnologies Inc.
Theratechnologies is a Canadian biopharmaceutical company specializing in drugs for the treatment of HIV and other metabolic disorders. This chart shows how the market values its commercial products and research pipeline. This value is based on the sales performance of its current drugs and the potential of its new developments.
P/E of the market segment - Pharma immune
This chart for biopharmaceutical companies serves as a benchmark for Theratechnologies. It reflects how investors value the sector on average. Comparisons with this chart help understand how the market values Theratechnologies' niche business, focused on treating metabolic disorders, particularly in HIV-infected patients, compared to biotechs in other sectors.
P/E of the market as a whole
Theratechnologies is a Canadian pharmaceutical company focused on HIV and oncology treatments. It is a niche player in highly competitive markets. This chart of overall pharmaceutical industry sentiment helps understand how investors view the prospects of smaller companies with narrow product portfolios.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Theratechnologies Inc.
Theratechnologies is a Canadian biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of HIV and oncology. This chart shows the expected sales of its niche products. The valuation is based on the sales volumes of its existing drugs and the success of clinical development in targeted cancer therapies.
%20P%2FE%20Theratechnologies%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Theratechnologies-Inc.&v=1772681780885 "Chart of the company's future (projected) P/E Theratechnologies Inc.")
Future (projected) P/E of the market segment - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of treatments for patients with rare diseases. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess how the market views its existing products and research programs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772681780892 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Theratechnologies is a biopharmaceutical company specializing in HIV and oncology treatments. Given the general market expectations shown by this chart, THTX's business is driven by medical needs. Sales of its existing drugs and success in developing new ones are the primary factors influencing the company's value, not general economic trends.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772681780901 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Theratechnologies Inc.
Theratechnologies is a Canadian pharmaceutical company specializing in developing drugs to treat rare diseases, particularly those related to HIV. This chart shows the financial results of the company, which operates in niche but important areas of medicine.
Profit of companies in the market segment - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in the treatment of patients with HIV. This chart shows profitability in the pharmaceutical sector. For THTX, this reflects their ability to commercialize niche drugs for the specific needs of HIV patients, which is their core competency and source of revenue.
Overall market profit
Theratechnologies is a Canadian biopharmaceutical company specializing in developing treatments for rare diseases, such as lipodystrophy in HIV-infected patients. This is a niche market with an unmet need. The company's success depends on its commercial products. This gross margin chart does not reflect the specifics of this market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Theratechnologies Inc.
Theratechnologies is a Canadian biopharmaceutical company specializing in the treatment of HIV and other diseases with unmet medical needs. The revenue projections presented here are dependent on sales of its existing drugs and the success of its oncology developments in clinical trials.
%20profit%20of%20the%20company%20Theratechnologies%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Theratechnologies-Inc.&v=1772681781017 "Graph of future (projected) profit of the company Theratechnologies Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Theratechnologies specializes in HIV treatment and develops oncology drugs. The profit forecast for this sector depends on the success of commercialization of its products and the results of clinical trials. This chart reflects analyst expectations for the future of the HIV and oncology drug markets, where innovation is constantly being pursued.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772681781019 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Theratechnologies is a biopharmaceutical company specializing in the treatment of metabolic disorders, particularly those associated with HIV. Its success depends on sales of its existing drugs. The revenue projections presented here impact healthcare budgets, which determine the availability of its drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772681781023 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Theratechnologies Inc.
Theratechnologies is a Canadian pharmaceutical company specializing in drugs for the treatment of HIV and other metabolic disorders. This chart shows how the market values its revenue from sales of niche products. This value depends on the commercial success of its drugs and the progress of clinical trials for new candidates.
P/S market segment - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly those related to HIV. This chart reflects the average revenue estimate for the sector, providing insight into how the market values Theratechnologies' niche products and commercial strategy.
P/S of the market as a whole
Theratechnologies is a Canadian biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly those related to HIV. Its success depends on sales of its existing products. This chart provides a general market backdrop for assessing investor sentiment regarding revenue prospects in this niche pharmaceutical market segment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Theratechnologies Inc.
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly HIV. This chart shows how investors estimate the company's future sales, reflecting the demand for its therapeutic solutions.
%20P%2FS%20Theratechnologies%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Theratechnologies-Inc.&v=1772681781079 "The graph of the company's future (projected) P/S Theratechnologies Inc.")
Future (projected) P/S of the market segment - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly HIV. This chart shows how the market values its existing products and its research and development in highly specialized therapeutic areas.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772681781091 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Theratechnologies is a Canadian biopharmaceutical company specializing in the treatment of HIV and other metabolic disorders. Their success depends on sales of existing drugs and R&D. This market optimism curve is important. It impacts the overall investment climate in biotech and the healthcare system's ability to afford specialized drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772681781101 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Theratechnologies Inc.
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly those related to HIV. This chart reflects revenue from sales of its approved products. Revenue growth depends on demand for its niche drugs and the successful expansion of their use.
Sales of companies in the market segment - Pharma immune
Theratechnologies is a biopharmaceutical company focused on developing and commercializing treatments for patients with rare diseases, particularly HIV. They have approved drugs on the market. Their revenue structure is generated by sales of these specialized therapeutics in North America and Europe.
Overall market sales
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly those related to HIV. This total revenue chart includes the healthcare sector, where THTX addresses important medical needs for specific patient groups, improving their quality of life.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Theratechnologies Inc.
Theratechnologies is a Canadian biopharmaceutical company specializing in drugs for the treatment of HIV and other metabolic disorders. This chart shows analyst expectations for sales of its commercialized products and the success of its development programs.
%20sales%20of%20the%20company%20Theratechnologies%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Theratechnologies-Inc.&v=1772681781161 "Schedule of future (projected) sales of the company Theratechnologies Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, such as HIV-associated lipodystrophy. This chart shows forecasts for niche pharmaceutical markets. It reflects the need for treatments in specific conditions where the company can achieve leadership positions.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772681781261 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Theratechnologies, a biotech company focused on HIV and oncology treatments, sees this chart as a reflection of healthcare priorities. The stable economic growth projected here provides funding for chronic disease treatments. This is essential for the commercial success of the company's drugs, which aim to improve patients' quality of life.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772681781293 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Theratechnologies Inc.
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly those related to HIV. Its profitability depends on sales of existing products and the success of new developments. This chart shows how the company balances commercial activities with investment in R&D.
Market segment marginality - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in the development of treatments for patients with HIV and other specific diseases. This metric reflects the commercial success of its niche products. A high score indicates a strong market position and high demand for its therapy.
Market marginality as a whole
Theratechnologies is a pharmaceutical company specializing in drugs for rare diseases, such as HIV-associated lipodystrophy. Its success depends on sales of existing products and R&D. This overall profitability chart is not relevant to the specifics of the orphan drug market, where patents and clinical need are paramount.
Employees in the company, segment and market as a whole
Number of employees in the company Theratechnologies Inc.
Theratechnologies is a Canadian biopharmaceutical company focused on commercializing drugs for rare diseases, particularly those related to HIV. This graphic shows the team marketing and selling these niche but life-saving drugs, addressing the needs of patients with specific medical conditions.
Share of the company's employees Theratechnologies Inc. within the market segment - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, such as HIV-associated lipodystrophy. Serving patients with special needs requires a focused commercial team. This chart demonstrates its strength in its narrow but important therapeutic niche.
Number of employees in the market segment - Pharma immune
Theratechnologies is a Canadian pharmaceutical company specializing in drugs for the treatment of rare diseases, particularly those related to HIV infection. This graphic shows a focused team working in a narrow therapeutic niche, providing life-saving medications to patients with specific medical needs.
Number of employees in the market as a whole
Theratechnologies Inc. is a biopharmaceutical company specializing in treating patients with rare diseases, such as HIV. The economic environment, reflected in the employment chart, is important for ensuring access to their therapies. Stable employment supports public and private health insurance programs that cover the costs of life-saving medications.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Theratechnologies Inc. (THTX)
Theratechnologies Inc. is a Canadian pharmaceutical company focused on treating rare diseases such as HIV. This chart reflects the model of a commercially successful biotech company. Their cost per employee will be moderate, as, unlike R&D startups, they have revenue and the need to employ sales and marketing staff.
%20of%20the%20company%20Theratechnologies%20Inc.%20(THTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Theratechnologies-Inc.-THTX&v=1772681781585 "Chart of market capitalization per employee (in thousands of dollars) of the company Theratechnologies Inc. (THTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, including HIV. The company combines R&D and sales. This chart shows how the market perceives the value of its product portfolio and research per employee compared to its competitors.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772681781594 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Theratechnologies is a Canadian biopharmaceutical company specializing in drugs for the treatment of HIV and other metabolic disorders. In this niche, this metric reflects the value of its commercialized products. It demonstrates how the company addresses specific patient needs while maintaining its market share.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772681781612 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Theratechnologies Inc. (THTX)
Theratechnologies is a Canadian pharmaceutical company focused on drugs for the treatment of HIV-related complications. This chart shows how their small commercial team monetizes these niche, already approved drugs. Efficiency here refers to the ability to maintain sales in a narrow segment.
%20Chart%20Theratechnologies%20Inc.%20(THTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Theratechnologies-Inc.-THTX&v=1772681781625 "Company Profit Per Employee (in thousands of dollars) Chart Theratechnologies Inc. (THTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Theratechnologies (THTX) is a biopharmaceutical company specializing in the development and commercialization of treatments for patients with rare (orphan) diseases, particularly in the field of HIV. This chart represents an industry benchmark. It reflects how effectively the company balances R&D and sales of its niche, yet life-saving, drugs for specific patient groups.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772681781675 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Theratechnologies (THTX) is a Canadian pharmaceutical company focused on commercializing niche drugs, primarily for the treatment of HIV-related complications. Their strength lies in sales, not R&D. This chart shows how effectively their sales team can sell these highly specialized drugs to patients and physicians.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772681781716 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Theratechnologies Inc. (THTX)
Theratechnologies is a biopharmaceutical company specializing in drugs for the treatment of HIV and other metabolic disorders. This chart shows its commercial performance. Its high revenue per employee is generated by sales of its approved drugs. Growth will depend on the success of new products and market expansion.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Theratechnologies-Inc.-THTX&v=1772681781750 "Sales chart per company employee Theratechnologies Inc. (THTX)")
Sales per employee in the market segment - Pharma immune
Theratechnologies (THTX) is a Canadian biotech company specializing in the treatment of HIV and hormonal disorders. They have commercial products, but these serve niche markets. This chart shows how effective their commercial and R&D model is in generating revenue per employee compared to pharmaceutical giants.
Sales per employee for the market as a whole
Theratechnologies is a Canadian biotech company. They have a commercial product (Egrifta) for the treatment of HIV-related complications and are developing oncology drugs. This graph shows the revenue generated by their commercial and R&D teams, balancing sales and development.
Short shares by company, segment and market as a whole
Shares shorted by company Theratechnologies Inc. (THTX)
Theratechnologies (THTX) is a Canadian pharmaceutical company specializing in HIV treatments (Egrifta, Trogarzo) and developing oncology drugs. This chart shows bearish bets. The rise in shorts may reflect concerns about increased competition in the HIV market or skepticism about their oncology pipeline.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Theratechnologies-Inc.-THTX&v=1772681781942 "Short Shares Chart for the Company Theratechnologies Inc. (THTX)")
Shares shorted by market segment - Pharma immune
Theratechnologies (THTX) is a Canadian pharmaceutical company specializing in drugs for the treatment of HIV and metabolic disorders. This chart reflects the overall sentiment in the pharmaceutical sector, showing how many investors doubt the commercial success of their niche drugs.
Shares shorted by the overall market
Theratechnologies (THTX) is a biotech company focused on HIV. This seems to be a stable market. However, THTX is a small, unprofitable company. When this chart shows rising panic, investors aren't niche-savvy. They're selling off all the unprofitable second-tier biotechs, fearing funding risks and competition.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Theratechnologies Inc. (THTX)
Theratechnologies (THTX) is a biotech company. The stock is volatile and dependent on R&D. This chart can surge above 70 on positive news (for example, about an HIV drug), but this is a risky area. Oversold territory (<30) is often associated with research setbacks, delays, or funding concerns, indicating pessimism.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Theratechnologies-Inc.-THTX&v=1772681782108 "RSI 14 indicator chart for the company's stock Theratechnologies Inc. (THTX)")
RSI 14 Market Segment - Pharma immune
Theratechnologies (THTX) is a biotech focused on HIV treatment (Egrifta) and oncology. The "Pharma-immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether THTX's growth is due to its R&D or whether the entire biotech sector is simply overheated by expectations.
RSI 14 for the overall market
Theratechnologies (THTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast THTX (Theratechnologies Inc.)
Theratechnologies (THTX) is a Canadian biopharmaceutical company specializing in the treatment of HIV-associated complications and oncology. This chart shows the average target price. It reflects analyst opinions on the sales of its approved drugs and the potential of its oncology pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-THTX-Theratechnologies-Inc.&v=1772681782247 "A chart showing analyst consensus forecasts for the expected stock price. THTX (Theratechnologies Inc.)")
The difference between the consensus estimate and the actual stock price THTX (Theratechnologies Inc.)
Theratechnologies is a Canadian biopharmaceutical company focused on commercializing drugs for the treatment of HIV patients. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in the growth of their current products and their oncology R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-THTX-Theratechnologies-Inc.&v=1772681782284 "A chart showing the difference between the consensus forecast and the actual stock price. THTX (Theratechnologies Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Theratechnologies is a Canadian biotech company focused on treating metabolic disorders in HIV patients. This chart shows analysts' overall expectations for the immunotherapy sector. It reflects whether experts believe there will be stable demand for niche drugs to treat the side effects of HIV therapy.
Analysts' consensus forecast for the overall market share price
Theratechnologies is a biopharmaceutical company focused on the niche HIV market. They don't treat the virus itself, but sell drugs (EGRIFTA) to combat its complications (lipodystrophy). This chart shows overall market sentiment. For THTX, operating in a "protective" but narrow niche, how these expectations (healthcare budgets) impact their sales is important. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Theratechnologies Inc.
Theratechnologies is a pharmaceutical company focused on niche markets. Their commercial products (EGRIFTA) serve HIV patients. They are attempting to use this cash flow to fund R&D in oncology. This chart summarizes their transition. It weighs their stable (but small) HIV business against their high-risk bets on cancer drug development.
AKIMA Market Segment Index - Pharma immune
Theratechnologies is a biopharmaceutical company specializing in drugs for the treatment of metabolic disorders, specifically lipodystrophy in HIV patients. This chart shows the average index for the immunopharmaceutical sector. It helps investors assess how Theratechnologies' highly specialized business model compares to the industry average.
The AKIM Index for the overall market
Theratechnologies is a Canadian biopharmaceutical company specializing in the treatment of HIV and metabolic disorders. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, with its commercial products and pipeline, compares to overall economic trends in healthcare.
